U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C27H33N3O6S
Molecular Weight 527.632
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLIQUIDONE

SMILES

COC1=CC=C2C(=C1)C(=O)N(CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C(=O)C2(C)C

InChI

InChIKey=LLJFMFZYVVLQKT-UHFFFAOYSA-N
InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)

HIDE SMILES / InChI

Molecular Formula C27H33N3O6S
Molecular Weight 527.632
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://edudrugs.com/G/Glurenorm/more.html | http://www.e-compendium.be/topdf/1969/spc/H | http://www.rlsnet.ru/mnn_index_id_183.htm

Glurenorm is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release. Minor skin allergies, gastric upsets and other non-specific side effects have been reported. Hypoglycaemic reactions have been reported but they are infrequent. Glurenorm effect increase butadion, chloramphenicol, tetracycline, coumarin derivatives, cyclophosphamide, sulfonamides, MAO inhibitors, thiazide diuretics, beta-blockers, salicylates, alcohol.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Glurenorm

Approved Use

Used in the treatment of diabetes mellitus type 2.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.65 μg/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIQUIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
0.87 μg/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIQUIDONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.1 μg × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIQUIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4.98 μg × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIQUIDONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIQUIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3.06 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLIQUIDONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 mg 2 times / day multiple, oral
Recommended
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Role of K+ -channels in homotaurine-induced analgesia.
2001 Jun
The effect of Glurenorm (gliquidone) on lenses and skin in experimental diabetes.
2001 Nov 1
Methylamine and benzylamine induced hypophagia in mice: modulation by semicarbazide-sensitive benzylamine oxidase inhibitors and aODN towards Kv1.1 channels.
2001 Oct
Antiaggregatory activity of hypoglycaemic sulphonylureas.
2002 Jul
Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry.
2002 Jun 15
Effect of pH and complexation on transdermal permeation of gliquidone.
2002 Sep
[Severe hypoglycemia in diabetics with impaired renal function].
2003 Feb 7
Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes.
2003 May 1
Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-beta-cyclodextrin.
2003 Nov
[Effect of liuwei dihuang pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients].
2004 Dec
[Gliquidon induced-desensitization of pancreatic beta cells and the partial reversion of responsiveness after the desensitization of exposure to drug in normal and STZ type 2 diabetic rats].
2004 May
Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations.
2004 Sep
Protective effects of glurenorm (gliquidone) treatment on the liver injury of experimental diabetes.
2005
Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients.
2010 Sep
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
2013 Nov
Patents

Sample Use Guides

45-60 mg daily in divided doses taken before meals. Maximum single dose 60 mg, maximum daily dose 180 mg.
Route of Administration: Oral
In Vitro Use Guide
Gliquidone inhibits the [3H]glibenclamide (0.5 nM) binding to the rat cortex membranes (0.5-0.8 mg/ml) – IC50=27.2 nM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:58:58 GMT 2025
Edited
by admin
on Mon Mar 31 17:58:58 GMT 2025
Record UNII
C7C2QDD75P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLURENORM
Preferred Name English
GLIQUIDONE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
ARDF 26
Code English
gliquidone [INN]
Common Name English
GLIQUIDONE [MART.]
Common Name English
Gliquidone [WHO-DD]
Common Name English
GLIQUIDONE [MI]
Common Name English
ARDF-26
Code English
1-CYCLOHEXYL-3-(((P-(2-(3,4-DIHYDRO-7-METHOXY-4,4-DIMETHYL-1,3-DIOXO-2(1H)-ISOQUINOLYL)ETHYL)PHENYL)SULFONYL)UREA
Systematic Name English
Classification Tree Code System Code
WHO-ATC A10BB08
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
WHO-VATC QA10BB08
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
NCI_THESAURUS C97936
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
Code System Code Type Description
PUBCHEM
91610
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
MERCK INDEX
m5748
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY Merck Index
SMS_ID
100000092780
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
ECHA (EC/EINECS)
251-463-2
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
EPA CompTox
DTXSID4023096
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
DRUG BANK
DB01251
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
CAS
33342-05-1
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
DRUG CENTRAL
1302
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
ChEMBL
CHEMBL383634
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
WIKIPEDIA
GLIQUIDONE
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
RXCUI
25793
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY RxNorm
FDA UNII
C7C2QDD75P
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
MESH
C010969
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
INN
3308
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
EVMPD
SUB07928MIG
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
NCI_THESAURUS
C72798
Created by admin on Mon Mar 31 17:58:58 GMT 2025 , Edited by admin on Mon Mar 31 17:58:58 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY